(Photo credit: SusanneSchulz/iStock via Getty Images).
Medical marijuana prices in German fell 31% over the course of a year while products containing at least 20% THC overwhelmingly dominated supply and demand, according to a study published in the September 2026 volume of the International Journal of Drug Policy.
Researchers from institutions in Germany and Denmark examined the supply and apparent demand for medical marijuana flower between December 2024 and November 2025, following Germany’s April 2024 decision to remove medical marijuana from the country’s list of narcotic drugs. The analysis was based on continuously collected information from a single online dispensary, including product prices, available stock and THC and CBD concentrations.
The number of flower products available at the dispensary increased from 266 in December 2024 to 401 by November 2025, with 996 distinct products appearing during the study period. Researchers estimated demand by tracking decreases in inventory over time.
Over the same period, the median price of a gram of flower fell 31%, from €8.64 to €5.95. The price per 10 milligrams of THC fell even further, declining 36%, from €0.37 to €0.23. Roughly half of the individual products underwent at least one price change, and reductions in price were associated with increases in demand.
High-THC products accounted for the large majority of the market examined. About 85% of available flower contained at least 20% THC, while products containing between 20% and 29.9% THC accounted for more than two-thirds of total estimated demand.
The researchers found that both price and THC concentration independently predicted demand. For every one-percentage-point increase in THC concentration, estimated product demand increased by about 13%. Meanwhile, demand declined substantially as prices increased.
The authors described the findings as evidence of a rapidly changing and increasingly competitive German medical marijuana market, with consumers showing a strong preference for cheaper flower containing relatively high concentrations of THC.
They also raised concerns about whether the pattern aligns with the clinical evidence surrounding medical marijuana, noting that much of the research supporting marijuana-based treatments has involved extracts or considerably lower-THC products.
“This case study suggests that a highly dynamic commercial market for medical cannabis is evolving in Germany,” researchers concluded, adding that demand for inexpensive, high-THC products may not align with public health principles.
